In both August and September, CLRB received non-dilutive funding in the form of grants and contract awards totaling $14 million dollars. Two million dollars was awarded from the National Cancer Institute SBIR and an additional $12 million from the University of Wisconsin. These grants demonstrate the significance and relevance of the PDC platform and of the potential of the CLR-131 program.
So as per the August and September Reports of the stock and the present status we see that dilution does not have a very drastic effect on the stock. Hence it is quite a stable stock
HAHAHA! Yeah ok. a) Tell you what, drop the other aliases and we let you stay and you can talk about this stock like a normal person. or b) Continue posting under several aliases and we just ban them all. You decide.
The results of the Presidential Elections will have favoring results for the company as the company is expecting new policies by President Trump that will benefit them and thus increase the valuation on the stock
